Tinlarebant (LBS-008)

Name: Tinlarebant (LBS-008) in Stargardt disease type 1: Economic impact of Stargardt disease type 1 on families
Published: 2026-09-14T15:39:06-04:00

Stargardt disease type 1

Manufacturer: Belite Bio
Regulatory submission: NDA submitted June 2026
Launch: Anticipated in March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Stargardt disease type 1

Economic impact of Stargardt disease type 1 on families

2 evidence topics · 1 source

Daily functioning, independence, and caregivers: caregiver needs

“Caregivers are necessary” (opens the source at this quote in a new tab)

Patient testimony: costs of assistive technology

“Uses technology to assist with vision loss, but it’s expensive, quickly becomes obsolete, and is not sustainable for most people.” (opens the source at this quote in a new tab)